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Abstract
Background: Limited brachial artery (BA) flow-mediated dilation during brachial artery reactivity testing (BART) has
been linked to increased cardiovascular risk. We report on the phenomenon of BA constriction (BAC) following
hyperemia.
Objectives: To determine whether BAC predicts adverse CV outcomes and/or mortality in the women’s ischemic
Syndrome Evaluation Study (WISE). Further, as a secondary objective we sought to determine the risk factors
associated with BAC.
Methods: We performed BART on 377 women with chest pain referred for coronary angiography and followed for a
median of 9.5 years. Forearm ischemia was induced with 4 minutes occlusion by a cuff placed distal to the BA and
inflated to 40mm Hg > systolic pressure. BAC was defined as >4.8% artery constriction following release of the cuff.
The main outcome was major adverse events (MACE) including all-cause mortality, non-fatal MI, non-fatal stroke, or
hospitalization for heart failure.
Results: BA diameter change ranged from -20.6% to +44.9%, and 41 (11%) women experienced BAC. Obstructive
CAD and traditional CAD risk factors were not predictive of BAC. Overall, 39% of women with BAC experienced
MACE vs. 22% without BAC (p=0.004). In multivariate Cox proportional hazards regression, BAC was a significant
independent predictor of MACE (p=0.018) when adjusting for obstructive CAD and traditional risk factors.
Conclusions: BAC predicts almost double the risk for major adverse events compared to patients without BAC. This
risk was not accounted for by CAD or traditional risk factors. The novel risk marker of BAC requires further
investigation in women.
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Introduction
Brachial artery reactivity testing (BART) for measurement of
flow-mediated dilation (FMD) has been widely used in clinical
research as a non-invasive measure of endothelial function. A
typical FMD response in persons with a healthy endothelium is
at least a 5% to 10% increase in the brachial artery diameter
following release of a constrictive cuff (reactive hyperemia).
Inadequate dilation following hyperemia signals endothelial
dysfunction and has been linked to cardiovascular (CV) risk
factors and conditions associated with atherosclerosis;
inadequate peripheral FMD response has also been associated
with coronary endothelial dysfunction [1-3]. We previously
reported on resting brachial artery diameter and FMD in 377
women with chest pain from the Women’s Ischemic Syndrome
Evaluation Study (WISE) who underwent coronary angiography
and risk factor assessment [4]. While impaired FMD was
weakly associated with obstructive CAD, after adjustment for
resting brachial artery diameter, FMD was not an independent
predictor of obstructive CAD in women with chest pain.
Although it is generally assumed that release of the blood
pressure cuff should result in an increase in the brachial artery
diameter, constriction has been encountered in prior studies.
This phenomenon has been largely ignored [3,5,6] or attributed
to blunted endothelial function [7,8]. A blunted vasodilator
response following cuff release has been shown to correlate
with cardiovascular events [1-3]. The present study presents
novel data showing a comparatively high rate of brachial artery
constriction in a unique population of women with ischemia
undergoing coronary angiography.
The WISE study is a multi-center study that aims to improve
the diagnostic reliability of cardiovascular testing in the
evaluation of ischemic heart disease in women. Using standard
procedures available in 1996-1999, brachial reactivity testing
(BART) was performed at baseline in a subsample of the study
population. The purpose of the present paper is to investigate
the phenomenon of Brachial Artery Constriction (BAC) in the
WISE and to ask the following questions: (1) What are the risk
factors associated with BAC, and (2) Does BAC predict
adverse CV outcomes and/or mortality?
Methods
Study Population
The study population consisted of 377 participants in the
WISE study who received BART at baseline evaluation. WISE
is a National Heart, Lung, and Blood Institute –sponsored multi-
center study of 936 women undergoing clinically ordered
coronary angiography for suspected myocardial ischemia [9].
The study population was a convenience sample based on
interest and availability of equipment within each clinical site.
The four clinical enrollment sites in addition to inclusion and
exclusion criteria have been described previously [9-11]. All
women provided signed informed consent for baseline
evaluations and follow-up by using forms and procedures in
accordance with institutional guidelines and approved by the
institutional review board at each WISE clinical site including
University of Pittsburgh Medical Center, the Allegheny County
General Hospital (both located in Pittsburgh, PA), the
University of Florida, Gainesville, FL, and the University of
Alabama at Birmingham, AL. The baseline demographic, risk
factor, and quantitative assessment of coronary angiography
measurements have also been described previously [9-11].
Brachial Artery Reactivity Testing (BART)
All vasoactive medications were withheld for ≥24 hours if
short-acting and ≥48 hours if long-acting. Resting brachial
artery diameter was measured with B-mode ultrasonography
with a 7.5-MHz probe with imaging recorded on Super VHS
tapes. Blood pressure cuff was placed distal to the brachial
artery and inflated to 44 mm Hg greater than systolic blood
pressure for 4 minutes. We acknowledge that other studies use
a 5 minute occlusion time [7,8], therefore our extent of reactive
hyperemia may be less and our results may not be directly
comparable to prior studies. Brachial artery diameter was
reassessed for 2 minutes after cuff deflation. Offline
quantitative analysis was performed at a core laboratory
(University of Pittsburgh) by investigators masked to subject
identifiers. Images were digitized, and calibrated electronic
calipers were used to measure brachial artery diameter with
the intima-media interface to define arterial borders. Three
measurements were made in each analyzed frame and
averaged (intraclass correlation coefficient between 2
independent observers = 0.94). We have previously published
on our core lab reproducibility which was obtained using
repeated reading of the same image not repeat testing [4].
FMD was calculated as FMD = 100x (peak diameter after cuff
deflation – resting diameter) / resting diameter. FMD was
treated as a continuous variable for our analysis. We defined
BAC as > 4.8% constriction following release of the blood
pressure cuff. The reason for choosing this cut-point was that it
represented 1 standard deviation below the mean, sufficient to
distinguish it from possible measurement error or other sources
of random variation. This cut-point was further verified by ROC
analysis to give the best prediction of MACE. While we have
called this BAC for convenience, we realize that we cannot
confirm with certainty that BAC represents true constriction
versus failure to dilate following release of the blood pressure
cuff.
Follow-up procedures
Follow-up was conducted by experienced site nurses or
physicians through telephone and/or mail contact at 6 weeks
and then yearly thereafter. Follow-up consisted of a scripted
interview. Each woman was queried about symptoms,
medication use, CV events since last contact, hospitalizations,
and diagnostic or revascularization procedures. In the event of
death, a death certificate was obtained. During this period,
follow-up information was collected for a median of 6.8 years.
Subsequently, we conducted a National Death Index (NDI)
search for all women who were still alive and obtained death
certificates. This extended the follow-up, only for mortality, to a
median of 9.55 years (interquartile range 8.2-10.3 years).
WISE investigators blinded to identifying and diagnostic
information classified all deaths as CV versus non-CV. A major
event was defined as a death, non-fatal MI, non-fatal stroke, or
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hospitalization for heart failure. A CV event was defined as CV-
related mortality, non-fatal MI, non-fatal stroke, or
hospitalization for heart failure.
Statistical analysis
We used ROC analysis to estimate the optimal cut-point for
defining BAC as a predictor of MACE. The resulting cut-point of
>4.8% constriction yielded 41 women (11%) with BAC.
Because of the small sample size of the BAC group, the area
under the curve (AUC) is small but significantly different from
chance (0.55 [95% confidence interval=0.51, 0.59]).
Comparisons between women with and without BAC were
performed by the t-test for continuous measures and by chi
square for dichotomous measures. Because age is a major
correlate in WISE of demographic characteristics and CAD risk
factors, all p-values in Table 1 (with the exception of age and
postmenopausal status) were adjusted for age using logistic
regression. A multivariable model predicting the presence or
absence of BAC based on major risk factors for CAD was
developed using logistic regression. In addition, we also
examined the correlation between nitroglycerin mediated
dilation and outcomes as well as baseline diameter and events.
Event rates were estimated using the Kaplan-Meier method
and the log-rank statistic to compare event-free survival time in
Table 1. Baseline Characteristics by Brachial Artery
Vasoconstriction (BAC).
Characteristic No BAC (n=336)BAC (n=41)Age-Adjusted p-Value
Age 57 ± 11 60 ± 13 0.16
Postmenopausal (%) 72 85 0.08
Non-white racea (%) 13 10 0.64
Obstructive CADb (%) 36 36 0.65
Diabetes (%) 18 22 0.63
≥3 CAD risk factorsc (%) 63 49 0.09
Hxd hypertension (%) 54 56 0.98
Hxd dyslipidemia (%) 50 38 0.07
Family hx of CAD (%) 72 54 0.017
BMIe ≥ 30 (%) 38 34 0.67
Ever smoked (%) 55 58 0.62
Prior MIf or revasc (%) 26 20 0.33
Recent aspirin use (%) 51 68 0.06
Recent psych med use (%) 19 32 0.046
Insulin levels uIU/mL 10 ± 10 16 ± 14 0.031
Hs-CRP mg/L 7 ± 13 11 ± 16 0.18
Pulmonary disease (%) 4 15 0.015
Estradiol levels pg/mL 42 ± 51 19 ± 15 0.007
FSHg levels mIU/mL 32 ± 24 47 ± 30 0.002
Postmeno HTh use (%) 48 34 0.19
a Non-white race includes 45 African American and 4 Hispanic women; b
Obstructive CAD defined as ≥50% stenosis in ≥1 major epicardial vessel; c CAD
risk factors includes diabetes, hx of dyslipidemia, hx of hypertension, family hx of
CAD, BMI ≥30, ever smoking, and prior MI or revascularization; d Hx=history; e
BMI=body mass index; f MI=myocardial infarction; g FSH=follicle stimulating
hormone; h HT=hormone therapy.
doi: 10.1371/journal.pone.0074585.t001
women with and without BAC. We used Cox proportional
hazards regression to assess the relationship between FMD or
BAC and major cardiovascular outcomes unadjusted as well as
adjusted for age. We also developed multivariable Cox
proportional hazards models based on the major risk factors for
major CV events (using Framingham risk criteria) in addition to
BAC. When a major risk factor was not significant, we used
proxy variables, for example, recent use of anti-hypertension
medication instead of history of hypertension and recent statin
use instead of history of dyslipidemia. We then forced the CAD
severity score (log transformation) into the model (Table 2,
Model 2). In addition, we evaluated other log transformations
and interaction terms. The validity of the proportional hazards
assumption of invariant relative risk was tested and found to be
satisfactory. All p-values of <0.05 were considered statistically
significant. All analyses were performed using the SAS 9.2
software (SAS, Cary, NC).
Results
Characteristics
The mean age was 58±11, ranging from 21 to 83 years. Most
women (74%) were postmenopausal, 13% were non-white,
primarily African American, and 59% had 3 or more CAD risk
factors that included diabetes, dyslipidemia, hypertension,
family history of CAD, BMI ≥ 30, ever smoking, and prior MI or
revascularization. A total of 137 (36%) had obstructive CAD
defined as ≥50% stenosis in ≥1 epicardial vessel. The mean
ejection fraction was 65.2% ± 9.8%.
The mean FMD was 3.8 ± 8.7, with a median of 2.8 and
interquartile range of -1.3 to 7.9. Of the 377 women, 231 (61%)
had FMD<5%, while 41 (11%) had BAC. There was no
difference in FMD distribution or presence of BAC across
clinical sites (p=0.50) (Figure 1).
Compared to the 559 WISE women not undergoing BART,
the 377 with BART testing were more likely to be white (87%
vs. 77%, p=0.0002). Although not differing in age or presence
of obstructive CAD, the women undergoing BART had, on the
average, more positive health indicators: they had a lower CAD
severity score (13.3±13.3 vs. 15.9±15.5, p=0.007), lower
Table 2. Independent Predictors of Major Cardiovascular
Events: Two Models.
Predictors Model 1 Model 2
 HR (95% CI) p-ValueHR (95% CI) p-Value
BACa 2.21 (1.30, 3.78) 0.004 1.96 (1.12, 3.43) 0.018
Age 1.03 (1.01, 1.05) 0.002 1.02 (1.00, 1.04) 0.058
Diabetes 1.59 (0.99, 2.53) 0.052 1.41 (0.87, 2.30) 0.16
Ever smoked 1.62 (1.05, 2.49) 0.029 1.43 (0.91, 2.23) 0.12
Recent anti-HTNb meds 1.89 (1.16, 3.08) 0.011 1.70 (1.03, 2.82) 0.039
Recent statin use 1.79 (1.14, 2.81) 0.011 1.31 (0.80, 2.14) 0.28
CADc severity score (log) - - 1.85 (1.40, 2.45) <0.001
a BAC = Brachial artery constriction; b HTN = hypertension; c CAD = coronary
artery disease
doi: 10.1371/journal.pone.0074585.t002
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systolic blood pressure (134±20 vs. 139±22, p=0.0007), better
functional capacity (Duke Activity Score Index (DASI) of
21.9±14.8 vs. 18.5±14.5, p=0.0006), and were less likely to
have diabetes (18% vs. 29%, p=0.0001) or take psychoactive
medications (20% vs. 37%, p<0.0001), anti-hypertension
medications (60% vs. 72%, p=0.0002), nitrates (26% vs. 41%,
p<0.0001), or aspirin (53% vs. 65%, p=0.0001). These
differences remained consistent even after statistical
adjustment for ethnic origin. Much of these differences can be
explained by the relatively low number of BARTs performed at
the Alabama WISE clinical site, a Southern state with a large
African American population, where BART was done on only
14% of its WISE women, compared to Allegheny General
Hospital in Pittsburgh that performed BART on 85% of its WISE
population, with the other clinical sites at intermediate
percentages.
Predictors of BAC
Table 1 gives the baseline characteristics for women with
versus without BAC. Although the women with BAC were
slightly older and more likely to be postmenopausal, these
differences were not statistically significant. Because of these
slight differences, however, we statistically adjusted all p-
values for age. No traditional or non-traditional CAD risk factors
aside from those in Table 1 with a p<0.05 were significantly
associated with BAC, including chronic use of vasoactive
medications such as statins, ACE inhibitors, beta blockers, or
angiotensin receptor blockers. In multivariate analysis, only
insulin levels (odds ratio = 1.05 [95% confidence interval =
1.01, 1.08], p=0.010), pulmonary disease (5.07 [1.35, 19.050],
p=0.016), and family history of CAD (0.38 [0.14, 1.00],
p=0.050) were independent predictors of BAC. The model
explained 13% of the variance and the c-statistic was 0.70
(data not shown).
Prediction of Major Adverse Events
Over a median of 9.5 years, a total of 83 (22%) women had a
major adverse event, including 57 (15%) deaths, and 26 (7%)
had a non-fatal MI, stroke, or hospitalization for heart failure.
The number of women with non-fatal events is an
underestimate since these data were only collected for a
median of 6.8 years of telephone and/or mail follow-up
compared to the longer-term death follow-up.
In unadjusted analyses, lower FMD was predictive of CV-
related death (HR = 0.95 [0.92, 0.99], p = 0.025). However,
after adjusting for age, this result became non-significant.
Conversely, FMD did not predict major adverse events (HR =
0.98 [95% confidence interval = 0.96, 1.01], p = 0.16),
cardiovascular events (HR = 0.97 [0.94, 1.005], p = 0.10), or
all-cause mortality (HR = 0.98 [0.95, 1.01], p = 0.13) (Data not
shown).
The women with BAC had higher rates of individual and
composite events than did those without BAC (Figure 2).
Despite the relatively low event rates, the difference for stroke
events almost reached statistical significance (p=0.056). Over a
median of 9.5 years, women with BAC had an almost doubled
death rate compared to those without BAC (p=0.010).
Figure 1.  Distribution of Brachial Artery Reactivity by Clinical Site.  
doi: 10.1371/journal.pone.0074585.g001
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Freedom from major adverse events is shown in Figure 3.
Women with BAC had a higher event rate that included all-
cause mortality and non-fatal MI, heart failure, or stroke.
Kaplan-Meier estimated events over 9.5 years were 22% in
women without BAC and 39% in women with BAC (p=0.004).
The relationship between BAC and adverse major events
remained unchanged (hazard ratio [95% confidence interval]=
2.21 [1.30, 3.78], p=0.004) in multivariate modeling controlling
for the major risk factors including: age, diabetes, smoking
history, and recent use of antihypertensive medications and of
statins (Table 2). When entering the angiographic CAD severity
score into the model, the effect of BAC was attenuated but
remained statistically significant (1.96 [1.12, 3.43], p=0.018)
(Table 2). In sensitivity analysis (data not shown), substituting
the presence of obstructive CAD for CAD severity in the model
similarly attenuated the effect of BAC but to a lesser extent
(2.12 [1.24, 3.62], p=0.006).
Response to Nitroglycerin (NTG)
We assessed brachial responses to sublingual NTG in a
subgroup of women (N=334). Flow-mediated and NTG-
mediated responses correlated moderately (r=0.45, p<0.0001).
Further, a smaller NTG response was associated with worse
outcome (HR = 0.96 (0.94, 0.98) p<.0001.
Baseline Diameter and Events
In this cohort, baseline diameter ranged from 2.0mm to
6.4mm with a mean of 3.7mm +/- 0.7mm. The correlation
between baseline diameter and FMD is -0.17 (p=0.001).
Although statistically significant, this correlation is not
substantively significant (in correlation analysis, the p-value is
more reflective of the sample size than of the strength of
association).
In women with no BAC (n=336), mean baseline diameter
was 3.6mm +/- 0.7mm; whereas, in women with BAC (n=41), it
was 3.9mm +/- 0.7mm (p=0.029). Therefore, collinearity
between baseline diameter and BAC is likely to be minimal.
In univariate analysis, baseline diameter is predictive of
major events (HR=1.05 (1.02, 1.08), p=0.0004.
On multivariate analysis, when baseline diameter is
substituted for BAC in the two models in table 2, the HR drops
to 1.03 (0.998, 1.06), p=0.07 in Model 1 and to 1.01 (0.98,
1.04), p=0.51 in Model 2.
Further adding BAC into the model, the p-value for baseline
diameter drops to 0.15 in Model 1 and 0.73 in Model 2. At the
same time, the effect of BAC is only slightly reduced: 2.07
(1.20,3.57) p=0.008 in Model 1 and 1.93 (1.10, 3.40) p=0.023
in Model 2.
Figure 2.  Adverse Outcomes at a Median of 6.8 years and 9.5 Years of Follow-Up.  
doi: 10.1371/journal.pone.0074585.g002
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Discussion
Our results demonstrate that BAC is prevalent (11%), largely
not predicted by traditional risk factors or CAD, and yet is
predictive of a two-fold increased major adverse event rate,
including mortality in women. In multivariate analysis, only
insulin levels, pulmonary disease, and family history of CAD
were independent predictors of BAC. Flow-mediated and NTG-
mediated responses correlated moderately and a smaller NTG
response was associated with worse outcome. Finally while
baseline diameter did predict adverse events in univariate
analysis, the result for baseline diameter became non-
significant when added into a multivariate model while the
result for BAC still remained significant.
Prior BAC reports
FMD by BART is typically reported in prior literature as a
mean value + standard deviation with no mention of the range
of values. As such, it is unknown how many prior studies have
encountered BAC. Several papers have reported the range of
their FMD values, and document a small percentage of patients
with constriction upon release of the blood pressure cuff
[3,5-8]. Sondergaard et al. studied BART in 119 patients with
ischemic heart disease. They report that 2 of their 31 patients
with ischemic episodes and at least 6 of their 88 patients
Figure 3.  Freedom from Major Cardiovascular Events by Presence vs. Absence of BAC.  
doi: 10.1371/journal.pone.0074585.g003
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without ischemic episodes had constriction upon release of the
blood pressure cuff (7% overall), many of which constricted
>5% (our definition of BAC). While only 29% of their population
was female, the percentage with BAC by sex was not
documented [5]. Teragawa et al. studied the relationship
between coronary and peripheral endothelial function (by
coronary reactivity testing and BART, respectively) in 41
patients with angiographically normal coronary arteries [3]. Two
of their 41 patients (5%) had constriction of the brachial artery
upon release of the blood pressure cuff, however neither
constricted >2%. Eighteen of their patients were women,
however the sex of the 2 patients with constriction is unknown.
Mitchell et al. evaluated FMD by BART in 2045 participants
from the Framingham Offspring Study [6]. They too showed
constriction in a small percentage of subjects (exact
percentage not published), however none constricted >2%.
Their data were presented by sex, and although not statistically
assessed, did not suggest a dramatic difference in rates of
constriction between men and women. Finally, Gori et al. have
demonstrated constriction following hyperemia in several of
their studies. Most notably at least 5 of 451 patients with chest
pain who underwent angiography [8] and 4 of 148 patients (24
with hypertension, 24 with congestive heart failure, 24 with
CAD, and 76 controls) [7] had constriction. In the latter cohort,
all 4 that constricted had congestive heart failure. Again none
constricted >5% and they were not differentiated by gender.
We found BAC in 11% of our patient population, all of whom
were women with suspected myocardial ischemia. Since
women were largely underrepresented in the above studies, it
is possible that our higher rate of constriction represents a
more severe vasoconstrictive response in women than men. It
is also possible that our population simply represents a sicker
patient population than those of Teragawa et al. and Mitchell et
al. although our percentage of BAC is even higher than
Sondergaard et al. who studied subjects with documented
ischemic heart disease and Gori et al. who found constriction
primarily amongst heart failure patients. Finally, the larger
proportion of constriction in our study may be reflective of a
shorter occlusion time and lower stimulus for dilation. In our
study, BAC predicted a two-fold increased major adverse event
rate, including mortality in women. Interestingly as seen in
Figure 2, only all-cause mortality was significant as an
individual endpoint. Since there was a higher prevalence of
pulmonary disease in the BAC group (Table 1), it cannot be
excluded that factors other than vascular reactivity could have
influenced the study results.
Proposed Mechanisms of BAC
We propose several potential mechanisms for the BAC found
in 11% of our WISE population. First, since the normal
response during the final 30 seconds of cuff occlusion is
constriction [12], it is possible that BAC represents a failure to
dilate with hyperemia as opposed to active vasoconstriction.
This would suggest that BAC is a severe form of low FMD, one
in which there is minimal NO-mediated dilation from severe
endothelial dysfunction.
Second, it is well documented that following peak hyperemic
flow, there is a time delay of FMD such that FMD occurs when
flow and shear stress have returned to near resting levels.
Various proposed mechanisms for this delay include a delay in
NO release or an initial opposing vasoconstrictor response that
is shorter lived than NO release. Jiang et al. studied these two
hypotheses and supported the latter explanation by
demonstrating that shear stress induced an immediate and
sustained NO-dependent decrease in vascular tone that was
offset by short-lived vasoconstriction [13]. This vasoconstriction
was a consequence of high flow and was caused by a
hydrostatic drop in mean arterial pressure along the upper limb
leading to a drop in transmural pressure distending the arterial
wall. While the authors concluded that FMD which is measured
at 30 seconds to 2 minutes after cuff release (when flow is
back to baseline) still remains a reliable measure of NO-
dependent vasodilation, it is possible in our patients with BAC
that this vasoconstrictor response was either stronger or more
prolonged than usual outweighing any NO-mediated
vasodilation.
Third, acetylcholine has been shown to evoke paradoxical
vasoconstriction in atherosclerotic coronary arteries, through
unopposed activation of muscarinic receptors on smooth
muscle cells [1]. It is possible that BAC represents active
vasoconstriction in a severely diseased vessel by a substance
such as acetylcholine.
Fourth, the traditional approach to FMD calculation
expresses the diameter at 60 seconds after cuff deflation
relative to the preceding baseline diameter. In a study by Black
et al., 42% of older subjects missed true peak dilation when
FMD was assessed continuously up to 90 seconds post cuff
deflation [14]. While we measured subjects up to 2 minutes
post cuff deflation, it is possible that we missed peak dilation in
those patients with BAC. Regardless, any constriction following
cuff deflation is abnormal and even if dilation occurred farther
out than 2 minutes; our current study results demonstrate that
BAC at 2 minutes is associated with an adverse prognosis.
Study Limitations
Our study has several limitations. First, due to the design of
the study, causality cannot be determined or implied. Second,
since clinically-indicated coronary angiography was performed
in all of our study patients, our results may not be generalizable
to non-angiographic populations of women. Third, our BAC
subgroup size was small with few major adverse events, thus
our study may not accurately estimate the true BAC-associated
risk. Further, our while our mean FMD is consistent with prior
studies, our standard deviation was large indicating a
heterogeneous study population. Despite the resulting low
statistical power, BAC emerged as a statistically significant
independent predictor of major adverse events. Fourth, we did
not time BART to a specific time in the menstrual cycle in
premenopausal women, increasing the variability in the
recordings and perhaps underestimating our results. We do not
believe this has significantly influenced our results since <25%
of women were premenopausal. Fifth, since a large proportion
of our BART recordings either did not have Doppler or the
signal was unacceptable we are unable to conclude whether
the BAC we encountered truly represents flow-mediated
constriction or simply a failure to dilate. Sixth, we do not have
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repeated scans to test the reproducibility of the BAC
measurement; future work should address this.
Conclusions
BAC was prevalent (11%), largely not predicted by traditional
risk factors or CAD, and yet predictive of a two-fold increased
major adverse event rate, including mortality in women. These
results suggest that vasoconstriction or severe failure to dilate
may play a relatively important role in ischemic heart disease
pathophysiology in women. Future studies should investigate
BAC in larger sample sizes, along with other measures of
vasoconstriction in order to further delineate the
pathophysiology and prognostic significance for women.
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